Gene Synthesis Market Size (USD 9.38 Bn) by 2033

Gene Synthesis Market Size, Trends and Advances Report

The global gene synthesis market size was estimated at US$ 2.1 billion in 2023 and is projected to grow US$ 9.38 billion by 2033, rising at a compound annual growth rate (CAGR) of 16.14% from 2024 to 2033. The growing demand for gene therapy and personalized treatments boosts the demand for gene synthesis.

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

• By region, North America dominated the gene synthesis market in 2023.
• By region, Asia Pacific is estimated to grow with the fastest CAGR during the forecast period.
• By method, the solid-phase synthesis segment held the largest market share in 2023.
• By service, the antibody DNA synthesis segment dominated the market in 2023.
• By service, the viral DNA synthesis is estimated to grow at the fastest rate during the forecast period.
• By application, the gene & cell therapy development segment held the largest share of the market in 2023.

Industry at a Glance

Gene synthesis is a dependable and economical technique that yields 100% sequence correctness in bespoke DNA constructs. DNA synthesis is a potent molecular biology method that has revolutionized modern biology and is quickly emerging as an essential component of the research workflow. Gene synthesis is often used in research and development projects in a variety of industries. The gene synthesis market has grown as a result of the growing uses of synthetic biology. Gene synthesis services are being outsourced to specialized organizations by a large number of university and research institutions, small biotech startups and firms. The market for gene synthesis has drawn large governmental and private investments. Gene synthesis infrastructure and technologies are receiving significant funding from governments, universities, and biotechnology corporations. Funding and research grants have made it easier to produce new products and upgrade technology, which has increased gene synthesis market growth.

Top Companies in the Gene Synthesis Market

• Boster Biological Technology
• OriGene Technologies, Inc.
• Integrated DNA Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• ProMab Biotechnologies, Inc.
• Biomatik
• ProteoGenix, Inc
• Twist Bioscience
• Brooks Automation, Inc. (GENEWIZ)
• GenScript

Twist Bioscience Pipeline in the Gene Synthesis Market

Integrated DNA Technologies Inc. Pipeline in the Gene Synthesis Market

Increasing Research & Development Drives Gene Synthesis Market

Gene synthesis has made an incredible contribution to the quickly changing field of drug research, from the creation of vaccines to new therapeutic targets to biologics. Biology research has been changed by gene synthesis technology. Scientists may now design or reprogram entire genomes and cells rather than being restricted to the traditional techniques of modifying one gene at a time. Technologies and methods for synthesizing DNA are rapidly establishing themselves as essential components of contemporary molecular biology and are essential to the study of synthetic biology. It is no longer an idea that complete genes, new genetic pathways, or even entire genomes may be synthesized.

Ethical Concerns Restraints the Gene Synthesis Market

The ethical considerations surrounding the use of gene drives and genetic engineering in conservation are often categorized as including risk assessment and management, opportunity costs, risk and benefit distributions, public acceptability and participation, and oversight. Although they are crucial, the ethical issues go beyond them since genetic engineering has the ability to drastically change the beliefs, methods, and values associated with conservation.

Growing Genetic Disorders Will Boost the Gene Synthesis Market’s Growth

There are now a lot of novel genetic illnesses being reported in the medical literature, in addition to the well over 6,000 established genetic disorders. There are several uncommon genetic diseases that have received far less attention and may not have been properly identified. Numerous substances found in both artificial and natural surroundings have the potential to damage a person's DNA. These agents may include alcohol, combustion products, viruses, and substances produced by fungi, bacteria, or plants; they may also include industrial chemicals, oxygen, UV and ionizing radiation, and combustion products. Owing to the extended half-lives of many of these substances, humans have developed defensive mechanisms to mitigate their negative effects as well as methods for repairing the harm that cannot be prevented. A multitude of variables are driving up the incidence of genetic abnormalities, which in turn is driving up demand for gene synthesis.

For instance,

• It is believed that between 263 million and 446 million people worldwide may be thought to have a rare disease. As of right now, more than 6,000 rare diseases are listed in the literature. The majority of rare diseases are chronic, with long-term health effects and a diminished quality of life. In addition, they pose a significant financial burden, with medical expenses in the US alone expected to cost between US$400 billion and US$1 trillion annually.

Report Highlights

Method Insights

By method, the solid-phase synthesis segment held the largest gene synthesis market share in 2023. Combinatorial chemistry, oligonucleotide, oligosaccharide, and peptide synthesis all make extensive use of solid-phase synthesis. Solid-phase synthesis offers several benefits for creating intricate peptide-based macrocycles. Easy purification, quick production of linear peptide intermediates, and experience with large-scale peptide synthesis are the general benefits of solid-phase synthesis. Simple equipment, ease of use, a single synthesis process, uniform and controllable particle sizes, minimal pollution, and the ability to prevent or lessen the hard agglomeration phenomenon—which is easily observed in the liquid phase—are just a few of the solid phase synthesis method's many notable benefits. Its cost is also cheap.

Service Insights

By service, the antibody DNA synthesis segment dominated the gene synthesis market in 2023. Various modified antibody molecules for study, diagnosis, and therapy have been developed as a result of advancements in recombinant monoclonal antibody (rAb) technology. A number of laborious processes are involved in developing antibody therapies, such as generating lead candidate genes, cloning them into vectors, and amplifying plasmids in Escherichia coli cells. The effective in vitro production of synthetic DNA products has been made possible by recent advancements in synthetic biology and automation. Recombinant antibodies (rAbs) have a wide range of uses in toxicological and biological research. Recombinant monoclonal antibodies are frequently employed as biochemical indicators and diagnostic instruments or in the development of potent therapeutic interventions that target autoimmune diseases, cancer, and a wide range of other illnesses.

By service, the viral DNA synthesis segment is estimated to grow at the fastest rate during the forecast period. The ability to chemically synthesize viral genomes offers researchers a novel and potent tool for examining the expression, function, and pathogenic potential of viral genes. If there's no natural viral template available, this approach comes in quite handy. On a scale that would be hard to do with traditional molecular biology techniques, it also permits the genetic manipulation of viral genomes.

Application Insights

By application, the gene & cell therapy development segment held the largest share of the gene synthesis market in 2023. Because genes may be artificially created for insertion or replacement, gene synthesis has the potential to completely transform the way tailored medications are administered. Patient care may be completely transformed by personalized medication. Using pharmacogenetic and pharmacogenomic data, this therapeutic approach recommends medications tailored to each patient. The foundation for a system that potentially helps millions of people is being laid by innovations in customized healthcare. Patient-centered best practices, actionable precision diagnostics, and effective precision therapy must be combined to scale personalized care to a more accessible and standardized level.

Regional Insights

By region, North America dominated the gene synthesis market in 2023. North America has a reputation for leading the market in the area when it comes to technical developments, research, and development. The market is growing at a large rate because of nations like the United States and Canada. Genetic problems are becoming more common and need both gene synthesis and gene therapy.

For instance,

• In the U.S., Down syndrome is the most often diagnosed chromosomal abnormality. Every year in the United States, about 5,700 babies are born with Down syndrome. This suggests that around 1 out of every 640 babies is born with Down syndrome.
• The most common kind of genetic blood ailment, sickle cell disease, is thought to affect between 70,000 and 100,000 people in the U.S. Black or African American people make up more than 90% of the population, with the remaining 3% to 9% being classified as Hispanic or Latino. It is estimated that Americans with sickle cell disease (SCD) will lose more than 20 years from their typical life expectancy. Hereditary hemochromatosis affects one in 300 people in the U.S. Type 1 hemochromatosis is one of the most common inherited diseases, affecting around a million people in the U.S.

With about 40% of the worldwide synthetic biology business, the U.S. leads the world in this field. Due to this, the U.S. is in a strong position to establish industry standards, therefore raising the bar for acceptable practice and holding businesses accountable for negligence if they fall short of it. Due to its market dominance, the U.S. is able to take the initiative that ought to inspire other nations with developing synthetic biology businesses to follow suit. Companies that produce synthetic DNA have a strong incentive to make sure they can meet the demand for their product since the U.S. government is a major sponsor of life sciences research.

For Instance,

• In October 2023, a historic Executive Order on the Safe, Secure, and Reliable Development and Use of Artificial Intelligence ("Executive Order") was signed by President Biden. The Executive Order instructs the federal government to enhance related biosecurity protocols and lower the likelihood of synthetic nucleic acid abuse under section 4.4(b). According to the Executive Order, OSTP must create a framework to motivate suppliers of synthetic nucleic acid sequences to put in place thorough, scalable, and verifiable screening procedures for the procurement of synthetic nucleic acids.

By region, Asia Pacific is estimated to grow with the fastest CAGR during the forecast period. The market for gene synthesis is growing at a rapid rate, and the largest region is Asia Pacific. The market is expanding as a result of nations like South Korea, China, Japan, and India. These nations are demonstrating government investment in biotechnology, genetic engineering, agriculture, and healthcare, as well as technical advancements.

India is one of the top 5 economies in the world and a major contributor to biotechnology and gene synthesis. The Indian government has launched a number of projects that support the expansion of the sector. The prevalence of genetic illnesses is rising in India as well, and gene synthesis will be necessary for both diagnosis and therapy. Rare genetic illnesses have gradually gained more attention in India in recent years, drawing the interest of researchers, medical professionals, and decision-makers.

Recent Developments in Gene Synthesis Market

• In June 2024, the industry-leading gene synthesis services provider GenScript Biotech Corporation, known for its unwavering innovation in synthetic biology, is thrilled to announce the debut of GenScript FLASH Gene service, the ultra-fast sequence-to-plasmid (S2P) service. This flagship product meets the pressing need to provide gene constructs with unparalleled speed, quality, and cost-effectiveness. The quickest S2P service in the market is GenScript's FLASH Gene service, which takes just four business days to get from sequencing to plasmid build. With a flat-rate price approach that starts at just $89, this ground-breaking service covers cloning, plasmid preparation, and gene synthesis.
• In February 2024, the company Ansa Biotechnologies, Inc., a leader in next-generation DNA synthesis, announced today that Jason T. Gammack will take over as CEO. Gammack is joining the firm as it gets ready to launch a full commercial service and wraps up its early access program for complicated synthetic genes and gene fragments. Dan Lin-Arlow, PhD, the company's founding CEO, will stay on and take on a new role as chief scientific officer.
• In June 2023, in-vitro transcription (IVT) messenger RNA (mRNA) synthesis service is to be launched on June 29, 2023, according to a statement from Eurofins Genomics Blue Heron, a biotechnology business focusing on advanced gene analysis. As to the press statement issued by the firm, the new synthesis service is intended to provide a comprehensive solution for researchers who are looking for quick turnaround times and high-quality, personalized MAb synthesis.

Segments Covered in Gene Synthesis Market Report

By Method

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

By Services

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

By Application

• Gene & Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait